Mylan MYL

  1. All
  2. Commentary
  3. Headlines
    1. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      integration than its larger global competitors Teva TEVA and Mylan MYL . Four major deals for a combined total of $105 billion ..... with Teva, Sandoz (a subsidiary of Novartis NVS), and Mylan . We estimate that these four companies have nearly 50

    2. Rate Hikes? Not in 2015

      Headlines

      Tue, 3 Mar 2015

      fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ..... on the right formulation while Mylan has had the generic market to itself. We knew Mylan would eventually face this competition

    3. Mylan ’s Ambitious Pipeline and Acquisitions Should Help Offset EpiPen Competition

      Commentary

      Tue, 3 Mar 2015

      Mylan ’s reported fourth-quarter results of 18 ..... management’s outlook for the year. We think Mylan ’s narrow economic moat remains intact. Following ..... skeptical of certain products in the pipeline, Mylan ’s ability to launch certain generic products

    4. UPDATE 1- Mylan still on the prowl for deals, perhaps one by end 2015

      Headlines

      Mon, 2 Mar 2015

      March 2 (Reuters) - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.

    5. Drugmaker Mylan's 4th-qtr profit rises on strong demand in N. America

      Headlines

      Mon, 2 Mar 2015

      March 2 (Reuters) - Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America.

    6. 2014's Biggest Stock Winners: Is There Any Gas Left in the Tank?

      Headlines

      Wed, 7 Jan 2015

      as a smaller player within the generics space, doesn't have the scale to compete with giants such as Teva TEVA and Mylan MYL . The stock's valuation isn't attractive, either, trading well above Krempa's $72 fair value estimate. Royal

    7. Mylan Posts Strong 3Q and Still Expects to Gain Tax Benefit From Abbott Pharma Inversion

      Commentary

      Fri, 31 Oct 2014

      changes to our fair value estimate for Mylan even after the company's reported ..... moderately surpassed our expectations. Mylan also benefited from some nonrecurring ..... over quality-control issues during Mylan 's acquisition of that firm's Agila

    8. Sanofi Issues Disappointing Diabetes Guidance, Leading to a Lower Fair Value Estimate

      Commentary

      Tue, 28 Oct 2014

      deteriorating pricing will likely remove some biosimilar threats to Lantus over the long term. We believe both Merck and Mylan will reevaluate launching biosimilars. Nevertheless, Lilly's biosimilar will likely still reach the market in Europe

    9. Abbott Posts Solid 3Q, but Vascular Devices Continues to Struggle

      Commentary

      Wed, 22 Oct 2014

      established pharmaceuticals segment. Now that the branded generics business in mature developed markets is being sold to Mylan , Abbott is set for robust growth focused on the emerging markets. While we do not expect that 13% growth is sustainable

    10. New U.S. Treasury's Plan to Limit Inversions Pressures Low-Tax Targets

      Commentary

      Tue, 23 Sep 2014

      specifically targets "spinversions" makes the Mylan /Abbott subsidiary deal less likely to proceed, hurting Mylan 's valuation. In this case, the valuation of Mylan (not Abbott) would be under pressure, given

    « Prev12345Next »
    Content Partners